Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Postma, Maarten, Fisman, David, Giglio, Roberto, Márquez-Peláez, Sergio, Nguyen, Van Hung, Pugliese, Andrea, Ruíz-Aragón, Jesús, Urueña, Analía, Mould-Quevedo, Joaquín
Formato: Artículo
Lenguaje:Inglés
Publicado: 2024
Materias:
Costo efectividad
Influenza
Vacuna mejorada
Acceso en línea:https://doi.org/10.3390/vaccines11061089
http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2043
Aporte de:
Repositorio Institucional Digital (RID ISALUD) de Universidad ISALUD

Ejemplares similares

Ejemplares similares